中文 | ENG

第58卷 第1期 2025-1
Ensuring authorship qualification in clinical research articles: A focus on surgical therapy studies

.........................

第58卷 第1期 2025-1
Estimated risk for transfusion of monkeypox contaminated perioperative blood transfusion: A call to action for stronger regulations and testing protocols

.........................

第58卷 第1期 2025-1
Insights into traumatic and crisis surgery: Implications of data analysis in conflict zones

.........................

第58卷 第1期 2025-1
Tongue peeling as an adverse reaction with use of micronized purified flavonoid: A case report

.........................

第58卷 第1期 2025-1
Pilonidal sinus of scrotum: A rare clinical entity

.........................

第58卷 第1期 2025-1
Incidental autopsy finding of retiform hemangioendothelioma of the spleen

.........................

第58卷 第1期 2025-1
Retroperitoneal laparoscopy for hydronephrosis due to multiple fibroepithelial polyps: A case series

.........................

第58卷 第1期 2025-1
Case reports of type 1 cystic biliary atresia—A rare variant of biliary atresia alongwith reviewof literature

.........................

第58卷 第1期 2025-1
The predictors of intraoperative surgical expenses in liver resection for hepatocellular carcinoma

.........................

第58卷 第1期 2025-1
Intracorporeal anastomosis versus extracorporeal anastomosis following laparoscopic right hemicolectomy: Surgical outcomes of a single-center observational study

.........................

第58卷 第1期 2025-1
Quality of life and spiritual health in motorcycle accident survivors: An analysis using the SF-36 Questionnaire and Spiritual Scale

.........................

第58卷 第1期 2025-1
Plastin 3 expression in circulating tumor cells as a predictor of cancer status in patients with prostate cancer

.........................

第57卷 第6期 2024-11
Emerging robot-guided techniques in endodontic microsurgery

.........................

第57卷 第6期 2024-11
Management of subcapsular hematoma after living donor liver transplant

.........................

第57卷 第6期 2024-11
Urethral pseudodiverticulum with left-sided nonfunctioning kidney: Case report

.........................

第57卷 第6期 2024-11
Strategy to minimize surgical defect of dermatofi brosarcoma protuberans

.........................

第57卷 第6期 2024-11
Rapunzel syndrome—An uncommon disease with varied common presentations

.........................

第57卷 第6期 2024-11
Minimally invasive approaches to management of acute necrotizing pancreatitis

.........................

第57卷 第6期 2024-11
Innovative surgical technique: Addressing ethical concerns

.........................

第57卷 第6期 2024-11
Emergency surgery and HIV screening, clinical or universal scenarios?

.........................
登入帳號才能閱讀全文
 
篇名 Lessening hepatic injury in cholestatic liver by optimal dietary docosahexaenoic acid supplementation in rats
作者 Guan‑Yeu Diau, Shih‑Ming Kuo, Chieh‑Wen Lin
卷期/出版年月 51卷3期 (2018/6)
頁次 91-97
摘要 Background: Dietary adjuvant management for the cholestatic liver disease before/after surgery is an important clinical issue. This study investigated the possibility for the dietary supplementation of docosahexaenoic acid (DHA) to treat cholestasis liver through the bile duct ligation (BDL) rat model. Materials and Methods: Thirty‑six male Wistar rats were divided into four groups (N: no BDL; BL, 1P, 5P: received BDL) and consumed either a regular diet (N, BL) or of DHA‑enriched diet (1P: at 1% and 5P: at 5% weight percentage) for 4 weeks. The liver fatty acids (FAs) profiles, serum aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase, interleukin‑2 (IL‑2), interferon γ (INF‑γ), and pathological examination with H and E, Masson, CD56 (natural killer cell), CD68 (macrophage) were examined. Results: The DHA dietary supplement increased liver DHA after BDL. Liver DHA N 8.09 ± 0.60% and BL 8.41 ± 0.55% were the lowest than the supplemented groups 1P 12.57 ± 1.16%, 5P 18.36 ± 2.00% (P = 0.000). However, liver arachidonic acid (20:4n‑6) 1P 23.13 ± 2.19% was the highest than N 18.86 ± 4.31%, BL 17.13 ± 3.07%, 5P 18.78 ± 1.76% (P = 0.001). The serum AST (U/L) in N 147.4 ± 28.2 and 1P 155.9 ± 35.1 were lower than B 317.1 ± 195.8, 5P 326.9 ± 141. 8 (P = 0.006). The serum alkaline phosphatase (U/L) showed the same trend N 49.8 ± 5.4, 1P 67.6 ± 21.1 were lower than the BL 172.2 ± 108.1, 5P 171.1 ± 149.1 (P = 0.017). Pathological examination with H and E, Masson revealed the fibrosis was prominent in BL, 5P. However, there were no significant differences in serum ALT, total bilirubin, IL‑2, INF‑γ, and immunohistochemical stain for the CD56, CD68. Conclusions: The results suggested that optimal dietary supplementing of DHA (1P) had less destruction and liver enzymes released after the BDL. However, higher enriched DHA (5P) could not benefit from this dietary treatment. The body weight did not increase even with this enriched high FAs diet after BDL for 4 weeks.
關鍵詞 Bile duct ligation, cholestasis liver disease, docosahexaenoic acid, hepatic injury
分類 Original Article

台灣外科醫學會雜誌 © 2006 Taiwan Surgical Association All Rights Reserved
會 址:台北市南京東路五段 31 號 3 樓
電 話:(02) 2769-7845 傳 真:(02) 2746-7149 Email: journal@surgery.org.tw